It seems that most industries are rushing to jump aboard the Twitter bandwagon. That's true for most cases, with the pharmaceutical industry being the exception. David Williams points out the lack of Twitter activity from the major pharmaceutical companies, where many of the Pharma-related keywords being owned by those not affiliated with the company. Worse, when he looks at the Twitter names for the top 10 prescribed drugs, they're owned by ...

Read more...

A recent study in Lancet becomes the first study to pull back the curtain on the Bill and Melinda Gates Foundation and its impact on global health. Since the money the Gates Foundation spends on global health (61% of its total $2.01 billion budget) is almost as large as the entire budget of the WHO, and because it is not a passive donor (it actively engages in policy making and ...

Read more...

Interesting case of a man detained at an airport because authorities couldn't fingerprint him. According to MedPage Today, he was taking the chemotherapy drug capecitabine which causes so-called hand-foot syndrome, or palmar-plantar erythrodysesthesia. The chronic inflammation causes the skin on the hands to peel and blister, which can eventually eradicate a patient's fingerprints. In a study looking at the drug, this type of inflammation occurs in about 65 percent of ...

Read more...

The story of Andy Behrman made the news a few weeks ago, most notably in The Wall Street Journal. Apparently, he was a bipolar "celebrity patient," and was paid $400,000 by Bristol-Myers Squibb for promoting their drug, Abilify. Things quickly went sour, as Mr. Behrman was afflicted with the drug's side effects, which included "dazed spells and agitation in his legs." Merrill Goozner comments on the case, casting the light on patient advocates, ...

Read more...

The FDA versus Cheeros furor is getting some blogosphere play. Internist Matthew Mintz analyzes the claim that Cheerios lowers cholesterol by 4 percent. Big deal, he says. "The problem is that even though Cheerios may lower your cholesterol by 4 percent, this probably has no impact on your risk for heart attack or stroke . . . it is clear that to derive benefit you need at ...

Read more...

The FDA sent a stern-sounding letter to the makers of Cheerios.

Not happy with their claims of being clinically proven to lower cholesterol, MedPage Today reports that Cheerios, by making "unauthorized health claims," is going to be treated as an "unapproved new drug."

Pharma watchdog John Mack thinks the FDA is going overboard by targeting Cheerios, with rampant, false claims by herbal and alternative supplements going ...

Read more...

The popular weight-loss supplement, Hydroxycut, has been recalled.

A 19-year old man died, and another needs a liver transplant. MedPage Today reports that these events occurred in 2007, but wasn't reported to the FDA until two years later. In all, 23 events were reported, ranging from the aforementioned serious side effects, to elevations in the liver enzyme levels.

Who knows how many more will be ...

Read more...

Here are some of the more interesting comments readers have left recently.

1. Carla Kakutani on the lack of primary care access in Massachusetts:
So we have a chicken and egg problem. Do we wait health care reform until we have revived US primary care, or is that even possible without health care reform to create the disruption needed to change our entrenched fee-for-service, procedure-happy payment ...

Read more...

The current strain of swine flu appears to be sensitive to the anti-virals Tamiflu and Relenza.

That's causing huge demand for these medications, with many pharmacies rapidly selling out. For instance, a typical pharmacy may fill one prescription of Tamiflu a week, but now, dispenses up to 25 packages per day.

There's clear stockpiling going on, and the doctors who acquiesce to patient demand share the ...

Read more...

Are drug companies putting money where their mouths are?

In a new trend, the pharmaceutical industry is offering what the NY Times calls, "money-back guarantees," essentially paying for treatments if their drug fails.

For instance, the makers of the osteoporosis drug Actonel will pay "$30,000 for a hip fracture . . and $6,000 for a wrist fracture," if a patient taking their drug suffers those conditions.

Read more...

Join 141,000+ subscribers

Get the best of KevinMD in your inbox

Sign me up! It's free. 
close-link
✓ Join 141,000+ subscribers 
✓ Get KevinMD's 5 most popular stories
Subscribe. It's free.
close-image